Cytek Biosciences, Inc. (CTKB) reported Q3 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $40.5 million versus the consensus estimate of $43.13 million.
GUIDANCE:
Cytek Biosciences, Inc. sees FY2022 revenue of $160-168 million, versus the consensus of $166.8 million.